Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 2/20 | 0.58 |
| ▸ | CACNA1G | O43497 | 7/20 | 0.57 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.56 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.56 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.56 |
| ▸ | ERN1 | O75460 | 1/20 | 0.56 |
| ▸ | HPGD | P15428 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | GLA | P06280 | 1/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.54 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12334148 | 0.99 | NPSR1 (0.58) | PARP1CACNA1GNPSR1CYP1A2CYP2D6 | |
| SCHEMBL13061007 | 0.93 | ERN1 (0.64) | PARP1CACNA1GNPSR1CYP1A2CYP2D6 | |
| SCHEMBL5476524 | 0.93 | SMYD2 (0.62) | PARP1HPGDKMT2AMEN1L3MBTL1 | |
| SCHEMBL13060642 | 0.91 | ERN1 (0.62) | PARP1CACNA1GNPSR1ERN1KMT2A | |
| SCHEMBL10264071 | 0.88 | CYP2C19 (0.69) | PARP1CYP1A2CYP2D6CYP2C9ERN1 | |
| SCHEMBL19634715 | 0.87 | PARP1 (0.58) | PARP1CACNA1GNPSR1CYP1A2CYP2D6 | |
| SCHEMBL13060850 | 0.86 | SMYD2 (0.67) | PARP1ERN1HPGDKMT2AMEN1 | |
| Hydrochloric Acid SCHEMBL2457432 | 0.85 | ALDH1A1 (0.56) | PARP1CACNA1GNPSR1CYP1A2CYP2D6 | |
| SCHEMBL842621 | 0.84 | HSD17B10 (0.70) | CACNA1GNPSR1CYP1A2CYP2D6CYP2C9 | |
| SCHEMBL8432036 | 0.84 | NPSR1 (0.70) | CACNA1GNPSR1CYP1A2CYP2D6CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090270381-A1 | Non-steroidal progesterone receptor modulators | BAYER SCHERING PHARMA AG (DE) | 2009-10-29 | — | — | US | disclosed |
| WO-2009077186-A1 | NONSTEROIDAL PROGESTERONE RECEPTOR MODULATORS | BAYER SCHERING PHARMA AKTIENGESLLSCHAFT (DE) | 2009-06-25 | — | — | WO | disclosed |
| EP-2070909-A1 | Non-steroidal progesterone receptor modulators | Bayer Schering Pharma AG (DE) | 2009-06-17 | — | — | EP | disclosed |
| US-20090075989-A1 | NON-STEROIDAL PROGESTERONE RECEPTOR MODULATORS | BAYER SCHERING PHARMA AG (DE) | 2009-03-19 | — | — | US | disclosed |
| WO-2008077646-A1 | NON-STEROIDAL PROGESTERONE RECEPTOR MODULATORS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2008-07-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090270381-A1 | Non-steroidal progesterone receptor modulators | PGR, PGRMC1, PGRMC2 | PARP1 2340/4885CACNA1G 1888/4885NPSR1 95/4885 |
| US-20090075989-A1 | NON-STEROIDAL PROGESTERONE RECEPTOR MODULATORS | NR5A1, CYP19A1, GPER1 | PARP1 2455/4885CACNA1G 1330/4885NPSR1 126/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.